SFRP1 reduction results in an increased sensitivity to TGF-β signaling

详细信息    查看全文

• 作者：Kelly J Gauger (1) (3)
  Kerry L Chenausky (2)
  Molly E Murray (3)
  Sallie S Schneider (1) (4)
  
• 刊名：BMC Cancer
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：11
• 期：1
• 全文大小：1005KB
• 参考文献：1. Hanahan D, Weinberg RA: The hallmarks of cancer. / Cell 2000, 100:57-0. CrossRef
  2. Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. / Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8621-623. CrossRef
  3. Reynisdottir I, Polyak K, Iavarone A, Massague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. / Genes & development 1995, 9:1831-845. CrossRef
  4. Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. / Bioessays 2001, 23:912-23. CrossRef
  5. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, / et al.: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. / The Journal of clinical investigation 2002, 109:1551-559.
  6. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL: Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. / Oncogene 2006, 25:3408-423. CrossRef
  7. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. / Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8430-435. CrossRef
  8. Polakis P: Wnt signaling and cancer. / Genes & development 2000, 14:1837-851.
  9. Brown AM: Wnt signaling in breast cancer: have we come full circle? / Breast Cancer Res 2001, 3:351-55. CrossRef
  10. Brennan KR, Brown AM: Wnt proteins in mammary development and cancer. / Journal of mammary gland biology and neoplasia 2004, 9:119-31. CrossRef
  11. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS: Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. / Proceedings of the National Academy of Sciences of the United States of America 1997, 94:6770-775. CrossRef
  12. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA: Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. / The Journal of biological chemistry 1999, 274:16180-6187. CrossRef
  13. Zhou Z, Wang J, Han X, Zhou J, Linder S: Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors. / International journal of cancer 1998, 78:95-9. CrossRef
  14. Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL: Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. / J Pathol 2002, 196:145-53. CrossRef
  15. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr R, Simon R, Sauter G, Leibiger H, / et al.: Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. / International journal of oncology 2004, 25:641-49.
  16. Gauger KJ, Hugh JM, Troester MA, Schneider SS: Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. / Cancer cell international 2009, 9:11. CrossRef
  17. Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G, Su MT, Bodmer R, / et al.: SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes. / The Journal of biological chemistry 1999, 274:20489-0498. CrossRef
  18. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F, Berx G: SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. / Nucleic acids research 2005, 33:6566-578. CrossRef
  19. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. / Anal Biochem 1987, 162:156-59. CrossRef
  20. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, / et al.: The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. / The Journal of clinical investigation 2009, 119:2678-690. CrossRef
  21. Miyazono K: Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. / Proceedings of the Japan Academy 2009, 85:314-23. CrossRef
  22. Sandler MA, Zhang JN, Westerhausen DR Jr, Billadello JJ: A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene. / The Journal of biological chemistry 1994, 269:21500-1504.
  23. Ignotz RA, Heino J, Massague J: Regulation of cell adhesion receptors by transforming growth factor-beta. Regulation of vitronectin receptor and LFA-1. / The Journal of biological chemistry 1989, 264:389-92.
  24. Giehl K, Imamichi Y, Menke A: Smad4-independent TGF-beta signaling in tumor cell migration. / Cells, tissues, organs 2007, 185:123-30. CrossRef
  25. Attisano L, Labbe E: TGFbeta and Wnt pathway cross-talk. / Cancer metastasis reviews 2004, 23:53-1. CrossRef
  26. Guo X, Wang XF: Signaling cross-talk between TGF-beta/BMP and other pathways. / Cell research 2009, 19:71-8. CrossRef
  27. Labbe E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL, Attisano L: Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. / Cancer research 2007, 67:75-4. CrossRef
  28. Hussein SM, Duff EK, Sirard C: Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2. / The Journal of biological chemistry 2003, 278:48805-8814. CrossRef
  29. James D, Levine AJ, Besser D, Hemmati-Brivanlou A: TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. / Development (Cambridge, England) 2005, 132:1273-282.
  30. Gauger KJ, Rodriguez-Cortes A, Hartwich M, Schneider SS: Rhodiola Crenulata inhibits the tumorigenic properties of invasive mammary epithelial cells with stem cell characteristics. / Journal of Medicinal Plants Research 2010., 5:
  31. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, / et al.: Molecular definition of breast tumor heterogeneity. / Cancer cell 2007, 11:259-73. CrossRef
  32. Baum O, Hlushchuk R, Forster A, Greiner R, Clezardin P, Zhao Y, Djonov V, Gruber G: Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. / International journal of oncology 2007, 30:325-32.
  33. Galliher AJ, Schiemann WP: Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. / Cancer research 2007, 67:3752-758. CrossRef
  34. Sheldrake HM, Patterson LH: Function and antagonism of beta3 integrins in the development of cancer therapy. / Current cancer drug targets 2009, 9:519-40. CrossRef
  35. Ulisse S, Baldini E, Sorrenti S, D'Armiento M: The urokinase plasminogen activator system: a target for anti-cancer therapy. / Current cancer drug targets 2009, 9:32-1. CrossRef
  36. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: Evolving role of uPA/uPAR system in human cancers. / Cancer treatment reviews 2008, 34:122-36. CrossRef
  37. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. / Nature medicine 1998, 4:923-28. CrossRef
  38. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ: Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. / Cancer research 2000, 60:5839-847.
  39. Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA: Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. / J Thromb Haemost 2006, 4:2710-715. CrossRef
  40. Maillard C, Jost M, Romer MU, Brunner N, Houard X, Lejeune A, Munaut C, Bajou K, Melen L, Dano K, / et al.: Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. / Neoplasia (New York, NY 2005, 7:57-6.
  41. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. / Cancer 2005, 103:1631-643. CrossRef
  42. Imamichi Y, Waidmann O, Hein R, Eleftheriou P, Giehl K, Menke A: TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. / Biol Chem 2005, 386:225-36. CrossRef
  43. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A: High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. / Nat Genet 2002, 32:153-59. CrossRef
  44. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. / Molecular cell 2001, 7:1267-278. CrossRef
  45. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, van Roy F, Berx G, Foidart JM, Gilles C: Regulation of vimentin by SIP1 in human epithelial breast tumor cells. / Oncogene 2006, 25:4975-985. CrossRef
  46. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM: Transactivation of vimentin by beta-catenin in human breast cancer cells. / Cancer research 2003, 63:2658-664.
  47. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/59/prepub
  
• 作者单位：Kelly J Gauger (1) (3)
  Kerry L Chenausky (2)
  Molly E Murray (3)
  Sallie S Schneider (1) (4)
  
  1. Baystate Medical Center, Pioneer Valley Life Sciences Institute, Springfield, MA, 01199, USA
  3. Department of Biology, University of Massachusetts, Amherst, MA, 01003, USA
  2. Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, MA, 01003, USA
  4. Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA, 01003, USA
  
• ISSN：1471-2407

文摘

Background Transforming growth factor (TGF)-β plays a dual role during mammary gland development and tumorigenesis and has been shown to stimulate epithelial-mesenchymal transition (EMT) as well as cellular migration. The Wnt/β-catenin pathway is also implicated in EMT and inappropriate activation of the Wnt/β-catenin signaling pathway leads to the development of several human cancers, including breast cancer. Secreted frizzled-related protein 1 (SFRP1) antagonizes this pathway and loss of SFRP1 expression is frequently observed in breast tumors and breast cancer cell lines. We previously showed that when SFRP1 is knocked down in immortalized non-malignant mammary epithelial cells, the cells (TERT-siSFRP1) acquire characteristics associated with breast tumor initiating cells. The phenotypic and genotypic changes that occur in response to SFRP1 loss are consistent with EMT, including a substantial increase in the expression of ZEB2. Considering that ZEB2 has been shown to interact with mediators of TGF-β signaling, we sought to determine whether TGF-β signaling is altered in TERT-siSFRP1 cells. Methods Luciferase reporter assays and real-time PCR analysis were employed to measure TGF-β transcriptional targets. Western blot analysis was used to evaluate TGF-β-mediated ERK1/2 phosphorylation. Migration chamber assays were utilized to quantify cellular migration. TERT-siSFRP1 cells were transfected with Stealth RNAi?siRNA in order to knock-down the expression of ZEB2. Results TERT-siSFRP1 cells exhibit a significant increase in both TGF-β-mediated luciferase activity as well as TGF-β transcriptional targets, including Integrin β3 and PAI-1. Phosphorylation of ERK1/2 is increased in TERT-siSFRP1 cells in response to enhanced TGF-β signaling. Furthermore, when the TGF-β pathway is blocked with a TGF-βR antagonist (LY364947), cellular migration is significantly hindered. Finally, we found that when ZEB2 is knocked-down, there is a significant reduction in the expression of exogeneous and endogenous TGF-β transcriptional targets and cellular migration is impeded. Conclusions We demonstrate that down-regulation of SFRP1 renders mammary epithelial cells more sensitive to TGF-β signaling which can be partially ameliorated by blocking the expression of ZEB2.